CNR1 and glaucoma: Importantly, a study of patients with unresponsive forms of glaucoma found that these patients responded well to cannabinoid-based therapy using a synthetic CB1 agonist.60 In an exploration of the potential to harness eCBs for the purpose of lowering IOP we offer several insights.